This Is MS Multiple Sclerosis Knowledge & Support Community

Swiss drugmaker Roche has said its experimental treatment for multiple sclerosis performed better in a late-stage clinical trial than a commonly used therapy for the most prevalent form of the condition... Read More - http://www.ms-uk.org/MSnews

MSUK wrote:Swiss drugmaker Roche has said its experimental treatment for multiple sclerosis performed better in a late-stage clinical trial than a commonly used therapy for the most prevalent form of the condition... Read More - http://www.ms-uk.org/MSnews

...Roche compared ocrelizumab with a placebo...

So a "Placebo" is the therapy for PPMS. Ya gotta laugh at the truth.

CureOrBust wrote:

MSUK wrote:Swiss drugmaker Roche has said its experimental treatment for multiple sclerosis performed better in a late-stage clinical trial than a commonly used therapy for the most prevalent form of the condition... Read More - http://www.ms-uk.org/MSnews

...Roche compared ocrelizumab with a placebo...

So a "Placebo" is the therapy for PPMS. Ya gotta laugh at the truth.

performed better in a late-stage clinical trial than a commonly used therapy for the most prevalent form of the condition

This part is related to the RRMS trial and they are talking abouth interferon-beta

This part is related to the RRMS trial and they are talking abouth interferon-beta

It's interesting that many of these new MAB drugs are compared in trials to the much older interferon type drugs and found to be "better". But for years there have been a number of articles that state these older drugs (CRABs) don't do much if anything for MS in the long run. So why test against something that really isn't much good for MS in the first place? I guess it's called slick marketing.